Patients and Caregivers
Welcome to WinRho.com
This website has been a resource for people seeking information about ITP and WinRho® SDF for 5 years. WinRho® is a first-line treatment option for Immune Thrombocytopenic Purpura (ITP) that may be helpful for you.
Baxter's commitment to hematologic therapy continues with WinRho® SDF - the first Anti-D immunoglobulin treatment for Immune Thrombocytopenic Purpura or ITP.
In studies of adult and pediatric ITP patients, WinRho® demonstrates excellent efficacy and duration of response — almost 90 days per treatment for adults and almost 37 days per treatment for children. The infusion time for WinRho® is only 3 to 5 minutes.1,2 Short infusion time means shorter time in your physician's office.
Indications and Usage1
WinRho® SDF must be administered via the intravenous route when used in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage in the treatment of non-splenectomized, Rho(D) positive:
- children with chronic or acute ITP,
- adults with chronic ITP, or
- children and adults with ITP secondary to HIV infection
The safety and efficacy of WinRho® have not been evaluated in clinical
trials for patients with non-ITP causes of thrombocytopenia or in previously
splenectomized patients or in patients who are Rho(D) negative.
WinRho® SDF should not be administered to:
- Rho(D) negative patients
- splenectomized patients
Please review the Full Prescribing Information and Important Safety Information.
- WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation,Winnipeg, Canada. Baxter Healthcare Corporation, Westlake Village, CA, USA, April 2006.
- Data on file, Cangene Corporation, Baxter Healthcare Corporation.
